High Multiplexing Liquid Array Assay Platform

高复用液体阵列检测平台

• 批准号: 7611293
• 负责人: DAVID M ROTHWARF
• 金额: $ 10万
• 依托单位: ARRAYOMICS, INC.
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-15 至 2010-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7611293
• 关键词: Allergic; Area; Biological Assay; Biomedical Research; Clinical; Code; Combinatorial Synthesis; Communicable Diseases; DNA Microarray Chip; Development; Diagnosis; Diagnostic; Disease; HIV; Heart Diseases; In Situ; Individual; Kidney Diseases; Libraries; Liquid substance; Liver diseases; Magnetism; Malignant Neoplasms; Marketing; Methodology; Microscope; Oligonucleotides; Optics; Performance; Phase; Process; Property; Protein Microchips; Proteins; Reader; Reading; Rheumatoid Arthritis; Sampling; Semiconductors; Small Business Innovation Research Grant; Surface; System; Techniques; Technology; Work; base; cost; design; flexibility; large scale production; magnetic beads; meetings; novel; outcome forecast; particle; prevent; protein expression; prototype; public health relevance; research study; resilience; response; success; tool

DESCRIPTION (provided by applicant): The aim of this project is to expand the capabilities of a novel `liquid array' platform, based on Encoded Sortable Particle (ESP) technology to make it cost and performance compatible with high multiplex assays. ESPs are optically-encoded microfabricated particles that can be manipulated using magnetic force. We will adapt our ESP-based liquid array system, which has already been successfully applied in the low multiplex space, to accommodate assays of 100,000-plex or more. ESP technology has broad applicability and should be a valuable tool in the diagnosis, prognosis, and characterization of a variety of disease states, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, liver disease, allergic responses, and infectious diseases (e.g. HIV). PUBLIC HEALTH RELEVANCE: ESP technology as applied to the high multiplex assay space will provide a broad platform for many different kinds of assays. The ESP platform is intrinsically versatile, and has the potential to be used in basic biomedical research, as well as high- throughput discovery and clinical diagnostics. The ability to control the particles magnetically (in a manner significantly different from magnetic beads) is a significant advantage. This technology should be useful in the diagnosis and prognosis of a variety of disease states, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, and infectious diseases (e.g. HIV).

描述（由申请人提供）：该项目的目的是扩展基于编码可选粒子（ESP）技术的新型“液体阵列”平台的能力，使其成本和性能与高复用分析相兼容。esp是光学编码的微制造粒子，可以用磁力操纵。我们将调整我们基于esp的液体阵列系统，该系统已经成功地应用于低复用空间，以适应100,000 plex或更多的分析。ESP技术具有广泛的适用性，应该成为各种疾病状态的诊断、预后和表征的有价值的工具，包括癌症、心脏病、关节炎和炎症性疾病、肾脏疾病、肝脏疾病、过敏反应和传染病（如HIV）。公共卫生相关性：ESP技术应用于多重检测领域，将为许多不同类型的检测提供一个广阔的平台。ESP平台本质上是通用的，有潜力用于基础生物医学研究，以及高通量发现和临床诊断。磁性控制颗粒的能力（以与磁珠明显不同的方式）是一个显著的优势。这项技术可用于各种疾病状态的诊断和预后，包括癌症、心脏病、关节炎和炎症性疾病、肾脏疾病和传染病（如艾滋病毒）。